The broad, long-term objective of this proposal for a cooperative drug discovery group is to meet the critical and urgent need for discovery of more effective and less toxic drugs and therapeutic regimens and modalities for treatment of toxoplasmosis in AIDS patient. Toxoplasmosis has emerged as a major cause of morbidity in patients with AIDS. Drugs that have proven effective in treatment of toxoplasmosis in AIDS are extremely limited and those most commonly used are frequently associated with drug reactions sufficiently severe to preclude their further use in a given patient. Thus, there is a real need to discover and evaluate new treatment modalities for toxoplasmosis in AIDS patients. The focus of this proposal is directed towards gaining new knowledge for the treatment of toxoplasmosis as it occurs in patients with AIDS. Its scope covers the areas of study of the in vitro and in vivo activity of new agents for treatment of toxoplasmosis and toxoplasmic encephalitis on the tachyzoite, cyst and bradyzoite forms of the parasite; Use molecular genetics in combination with drug resistant mutants to gain an understanding of the target of a given drug's action; and to develop a strategy to interrupt both acute and reactivation of toxoplasmosis based on the necessity of T. gondii motility in host cell invasion and the unique mechanism of parasite movement.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI030230-05
Application #
2065518
Study Section
Special Emphasis Panel (SRC (85))
Project Start
1990-06-01
Project End
1997-11-30
Budget Start
1994-12-01
Budget End
1995-11-30
Support Year
5
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Palo Alto Medical Foundation Research Institute
Department
Type
DUNS #
622276137
City
Palo Alto
State
CA
Country
United States
Zip Code
94301
Saeij, J P J; Boyle, J P; Coller, S et al. (2006) Polymorphic secreted kinases are key virulence factors in toxoplasmosis. Science 314:1780-3
McFadden, D C; Tomavo, S; Berry, E A et al. (2000) Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol 108:12-Jan
McFadden, D C; Boothroyd, J C (1999) Cytochrome b mutation identified in a decoquinate-resistant mutant of Toxoplasma gondii. J Eukaryot Microbiol 46:81S-82S
Liesenfeld, O; Kang, H; Park, D et al. (1999) TNF-alpha, nitric oxide and IFN-gamma are all critical for development of necrosis in the small intestine and early mortality in genetically susceptible mice infected perorally with Toxoplasma gondii. Parasite Immunol 21:365-76
Boothroyd, J C; Hehl, A; Knoll, L J et al. (1998) The surface of Toxoplasma: more and less. Int J Parasitol 28:3-9
Black, M W; Boothroyd, J C (1998) Development of a stable episomal shuttle vector for Toxoplasma gondii. J Biol Chem 273:3972-9
Neyer, L E; Kang, H; Remington, J S et al. (1998) Mesenteric lymph node T cells but not splenic T cells maintain their proliferative response to concanavalin-A following peroral infection with Toxoplasma gondii. Parasite Immunol 20:573-81
Manger, I D; Hehl, A B; Boothroyd, J C (1998) The surface of Toxoplasma tachyzoites is dominated by a family of glycosylphosphatidylinositol-anchored antigens related to SAG1. Infect Immun 66:2237-44
Manger, I D; Hehl, A; Parmley, S et al. (1998) Expressed sequence tag analysis of the bradyzoite stage of Toxoplasma gondii: identification of developmentally regulated genes. Infect Immun 66:1632-7
Subauste, C S; Fuh, F; de Waal Malefyt, R et al. (1998) Alpha beta T cell response to Toxoplasma gondii in previously unexposed individuals. J Immunol 160:3403-11

Showing the most recent 10 out of 55 publications